SPOTLIGHT -
7 TiP Randomized, Multicenter, International Phase 3 ARTEST Study to Evaluate the Efficacy and Safety of Enobosarm Versus Active Control for the Treatment of AR+, ER+, HER2– Metastatic Breast Cancer in Patients Who Previously Received an Estrogen-Blocking Agent and CDK4/6 Inhibitor
Erica L. Mayer, MD, MPH, Discusses New Targeted Therapies in Breast Cancer Treatment
The expert explained her research focused on the role of CDK4/6 inhibitors in treating breast cancer.
